Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Advanced melanoma is a highly aggressive malignancy that frequently exhibits resistance to conventional radiotherapy and single-agent immunotherapy. This study aims to evaluate the safety and tolerability of an innovative melanoma-specific aggregable gold nanosystem (Au-TMP) in patients with advanced melanoma. This single-arm, open-label, Phase 1a clinical trial utilizes a dose-escalation design, where participants receive a single intratumoral injection of Au-TMP followed by sequential radiotherapy and Toripalimab (anti-PD-1) treatment. This trial aims at assessing the safety of intratumoral injection of Au-TMP and radiotherapy in combination with anti-PD-1 therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub starszy
- •Zaawansowany czerniak (stopień III lub IV), którego nie można operować
- •Brak wcześniejszego leczenia systemowego (chemioterapii lub immunoterapii)
- •Co najmniej jeden widoczny guz, który można wstrzyknąć i napromieniować
- •Dobre funkcjonowanie nerek, wątroby i serca potwierdzone badaniami
- •Oczekiwana długość życia co najmniej 16 tygodni
- •Zgoda na antykoncepcję podczas badania
- •Dobry stan ogólny do samodzielnej opieki (ECOG 0-1)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
West China Hospital, Sichuan University
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Trial contact
Xingchen Peng, Professor
Yuting Yan, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.